Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diazoltec (Shuang Zuo Tai) is a fixed-dose combination vaginal therapy widely used in China for the treatment of mixed vaginal infections, including bacterial vaginosis (BV), vulvovaginal candidiasis (VVC), and trichomonal vaginitis. It contains three active ingredients: metronidazole, a nitroimidazole antimicrobial that targets anaerobic bacteria and protozoa by causing DNA strand breakage; clotrimazole, an azole antifungal that inhibits the enzyme lanosterol 14-alpha demethylase to disrupt fungal ergosterol synthesis; and chlorhexidine acetate, a broad-spectrum antiseptic that disrupts microbial cell membranes. The effervescent tablet formulation is designed for vaginal administration, providing rapid dissolution and comprehensive antimicrobial coverage against the diverse pathogens involved in complex vaginal dysbiosis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on metronidazole + clotrimazole + chlorhexidine acetate.